Subscription Center
Jul 30, 2008
A drug called PBT2, developed by Australian company Prana Biotechnology, appears to improve cognitive abilities in patients with early-stage Alzheimer's disease. Researchers report in Lancet Neurology, that it was also successful in reducing protein buildup associated with the debilitating neurodegenerative illness, which plagues up to 4.5 million Americans.
Craig Ritchie, a neuroscientist at Imperial College London and Prana consultant, says that the success of the recent 12-week trial (which had 78 participants) -- must be replicated in a larger longer-term trial before the company would consider seeking approval to sell it as an Alzheimer's therapy. "Our hope is that we might be able to see treatments that can substantially improve the lives of people with Alzheimer's disease within the next five or so years," he said in a statement.
See what we're tweeting about
gmusser The Trystero may become real, courtesy of Twitter. http://t.co/wu4cZhdN0R
Horganism Ishmael: "All men live enveloped in whale-lines. All are born with halters round their necks."
Dhunterauthor Nuevo Verdad: Geotrippin’ Parte the – Oh, Crap, I Forgot Cape Blanco!: Going through photos for the next insta... http://t.co/Sj3ldKqzuD
Deadline: Jul 15 2013
Reward: $5,000 USD
SciBX: Science-Business eXchange, a joint publication from the makers
Deadline: Aug 31 2013
Reward: $100,000 USD
The Geoffrey Beene Foundation Alzheimer’s Initiative (GBFAI) is launching the 2013 Geoffrey Beene Global NeuroDiscovery Challenge whose
Powered By: 
YES! Send me a free issue of Scientific American with no obligation to continue the subscription. If I like it, I will be billed for the one-year subscription.
